About Acalabrutinib API
Therapeutic Category Oncology
CAS Number
870524-78-5
API Technology
Small molecule
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of Action
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.
Indication
The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Dasatinib (Monohydrate)
Oncology
Adagrasib
Oncology
Fruquintinib
Oncology
Tucatinib
Oncology
Ripretinib
Oncology
Bortezomib
Oncology
Cabazitaxel
Oncology
Cabozantinib Hydrochloride
Oncology
Cabozantinib S-Malate
Oncology
Capecitabine
Oncology
Carfilzomib
Oncology
Decitabine
Oncology
Deucravacitinib
Oncology
Eribulin Mesylate
Oncology
Lomustine
Oncology
Nilotinib Hydrochloride Monohydrate (Form B)
Oncology
Olaparib (Form A)
Oncology
Palbociclib
Oncology
Pazopanib
Oncology
Pemetrexed Disodium Heptahydrate
Oncology
Acalabrutinib
Oncology
Capivasertib
Oncology
Lenalidomide (Form A)
Oncology
Midostaurin (Amorphous and Form II)
Oncology
Lenvatinib Mesylate (Form C and MIBK Solvate)
Oncology
Enzalutamide (Crystalline & Premix)
Oncology
Pomalidomide
Oncology
Gemcitabine Hydrochloride
Oncology
Abiraterone Acetate
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Zoledronic Acid
Oncology
Venetoclax
Oncology
Azacitidine
Oncology
Bendamustine Hydrochloride
Oncology
Relugolix
Oncology